[Immunocorrective therapy of the traumatic syndrome].
Saakov. B A BA; Belovolova. R A RA; Bakhutashvili. V I VI
Key Findings
- Combined thymalin and plaferon doubled 7‑day survival in rats after traumatic shock.
- The treatment increased total T‑lymphocyte numbers and the activity of lysozyme in the blood.
- The most pronounced immune effects were seen on day 7 post‑injury.
Practical Outcomes
- While the results hint that thymalin may have immune‑supporting properties, the study was done in rats with acute trauma, not in healthy humans. There’s no clear dosage or protocol for longevity or performance use, so biohackers should wait for human trials before considering it for self‑experimentation.
Summary
In a rat study, giving the peptide thymalin together with plaferon after a severe injury doubled the animals' chances of surviving the first week. The combo also boosted several immune markers, like total T‑cells and lysozyme activity, suggesting it helped the immune system recover from trauma.
Abstract
The effect of combined application of thymalin and plaferon in the prophylaxis and treatment of traumatic syndrome has been investigated in rats. The survival rate was taken as the criterion of efficiency, the mechanism of the effect obtained being estimated at the level of immunological protective factors. Traumatic shock was induced by Kennon's method in Wistar male rats weighing 200-250 g. Post-traumatic syndrome has been observed within 7 days. The combined application of thymalin and plaferon has increased the survival rate twice within the first 7 days. Immunomodulating effect of the combined application of thymalin and plaferon on the 7th day of traumatic syndrome was most marked at the level of total T-lymphocyte population, theophylline-sensitive T suppressors and lysozyme blood serum activity.
Study Information
pubmed
1987